MicroRNA 892C: A Potential Drug Target and Biomarker for Cancer

Target Name: MIR892C

NCBI ID: G102466721

MIR892C

Other Name(s): MicroRNA 892c | hsa-miR-892c-3p | hsa-miR-892c-5p | microRNA 892c | hsa-mir-892c

MicroRNA 892C: A Potential Drug Target and Biomarker for Cancer

MicroRNA 892C (MIR892C) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. MIR892C is a key regulator of cell proliferation and has been shown to play a role in the development and progression of various diseases.

The discovery of MIR892C as a potential drug target and biomarker comes from a team of researchers at the University of California, San Diego (UCSD), led by Dr. Qin Liu. The researchers identified MIR892C as a potential drug target based on its ability to interact with and inhibit the activity of the protein PDGF-BB, which is involved in cell proliferation and has been linked to the development of various diseases, including cancer.

To further validate the potential of MIR892C as a drug target, the researchers conducted experiments to determine its effects on cell proliferation and to investigate its potential as a biomarker for disease. The results of these experiments demonstrated that MIR892C can inhibit the activity of PDGF-BB and cause cell proliferation to slow down in a variety of cell types.

The researchers also used RNA sequencing to identify MIR892C-containing gene expression profiles in cancer cells and to compare them to those of non-cancer cells. They found that MIR892C was highly expressed in cancer cells and that its expression was associated with the development and progression of cancer.

In addition to its potential as a drug target, MIR892C has also been identified as a potential biomarker for disease. The researchers used MIR892C as a reference to identify gene expression profiles in samples from cancer patients and found that MIR892C expression was significantly altered in these samples compared to those from non-cancer patients.

The implications of these findings are significant. MIR892C has the potential to be a valuable drug target for the treatment of various diseases, including cancer. The researchers are currently working to develop MIR892C as a drug and are exploring its potential as a biomarker for disease.

Overall, the discovery of MIR892C as a potential drug target and biomarker is a promising development in the field of cancer research. Further studies are needed to fully understand its potential and to develop effective treatments for the treatment of various diseases.

Protein Name: MicroRNA 892c

The "MIR892C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR892C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets